When can immunotherapy be initiated in a patient undergoing anti‑tuberculosis treatment after achieving microbiologic conversion and clinical stability?

When to Initiate Immunotherapy in TB Patients

Immunotherapy (checkpoint inhibitors) can be initiated at least 2 weeks after starting anti-tuberculosis treatment in patients with active TB, or at least 2 weeks before starting immunotherapy in patients with latent TB infection (LTBI). 1

For Active TB During Immunotherapy

Timing of Immunotherapy Re-initiation

• A minimum 2-week interval of anti-tuberculosis treatment is recommended before restarting immunotherapy after active TB is diagnosed during checkpoint inhibitor therapy 1
• This recommendation is extrapolated from anti-TNF therapy data, where 4 weeks of chemoprevention with isoniazid significantly reduces MTB reactivation risk 1
• The 2-week minimum represents a pragmatic balance between controlling infection and avoiding cancer progression 1

Monitoring Requirements

• Close monitoring for overlapping hepatotoxicity is mandatory when anti-TB treatment and immunotherapy are given concurrently or sequentially 1
• Monthly clinical monitoring for signs of hepatitis during anti-TB therapy is essential 1
• Constitutional symptoms (fever, weight loss) require evaluation for TB before attributing them to cancer progression or immune-related adverse events 1

For Latent TB Infection (LTBI)

Pre-immunotherapy Prophylaxis Strategy

• Initiate LTBI chemoprophylaxis at least 2 weeks before starting checkpoint inhibitors to ensure patient tolerance of anti-TB prophylaxis 1
• Standard LTBI regimens include: 4 months rifampin, 9 months isoniazid, or 3 months weekly isoniazid plus rifapentine 1
• While CDC guidelines suggest concurrent initiation with anti-TNF agents is acceptable 1, the 2-week lead time is more prudent for checkpoint inhibitors 1

Special Considerations

• In adjuvant immunotherapy settings, delaying checkpoint inhibitors until LTBI chemoprophylaxis completion may be reasonable 1
• For advanced cancer requiring urgent treatment, a minimum 2-week course of TB therapy before immunotherapy initiation is acceptable 1
• The main concern is additive hepatotoxicity between isoniazid and checkpoint inhibitors 1

High-Risk Populations Requiring Screening

• Patients on dual immunotherapy (nivolumab plus ipilimumab) or combined immuno-chemotherapy require mandatory LTBI screening before treatment 1
• These patients have higher rates of immune-related adverse events requiring steroids, which further increases MTB reactivation risk 1
• 79.6% of checkpoint inhibitor-associated infections occur within the first 6 months of treatment 1

Critical Pitfalls to Avoid

• Do not assume constitutional symptoms represent cancer progression or immune-related adverse events without ruling out TB 1
• Avoid initiating corticosteroids for suspected immune-related adverse events before excluding active TB 1
• The use of additional immunosuppressive agents (corticosteroids, infliximab) increases serious infection incidence to 13.5% versus 2% without them 1
• Most TB reactivation cases occurred in patients NOT receiving corticosteroids or TNF-α inhibitors, suggesting checkpoint inhibitors may directly cause reactivation 1

Evidence Quality Note

The recommendations are based on extrapolation from anti-TNF therapy data and expert consensus (evidence level V, grade C) 1, as no randomized controlled trials exist specifically for checkpoint inhibitors and TB. The 2021 Spanish Melanoma Group guidelines 1 and 2019 Journal for ImmunoTherapy of Cancer recommendations 1 provide the most recent expert guidance on this topic.